The impact of steatosis on liver stiffness measurement in patients with chronic hepatitis B.
Recently, several studies have indicated that liver stiffness measurement (LSM) using FibroScan accurately predicts liver fibrosis. This study investigated the impact of steatosis on LSM in patients with chronic hepatitis B (CHB). The study prospectively enrolled 162 patients (106 men and 56 women) with CHB who underwent both a liver biopsy and LSM between January 2005 and June 2008. We examined the overall univariate correlation between steatosis and LSM value and also performed a multivariate regression analysis to identify independent variables influencing LSM values. The mean age of the patients was 44.4 years and the mean body mass index was 23.3 +/- 2.8kg/m2. The fibrosis stage ranged from F1 to F4 in 16 patients (9.9%), 37 (22.8%), 17 (10.5%) and 92 (56.8%), respectively. Steatosis was S0 in 128 patients (79.0%), S1 in 28 (17.3%), S2 in 6 (3.7%) and S3 in none. No overall significant correlation was noted between LSM value and steatosis (r = 0.023, p = 0.770). In the multivariate linear regression analysis, only fibrosis stage showed statistical significance (r = 0.268, p < 0.001), while steatosis did not (r = 0.013, p = 0.841). Our findings suggest that mild to moderate steatosis does not have a significant impact on LSM values in patients with CHB.